These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 3997205

  • 1. Hydralazine and isoniazid reduce the formation of soluble immune complexes by complement.
    Schifferli JA.
    Immunol Lett; 1985; 9(5):297-9. PubMed ID: 3997205
    [Abstract] [Full Text] [Related]

  • 2. Drugs that induce systemic lupus erythematosus inhibit complement component C4.
    Sim E, Gill EW, Sim RB.
    Lancet; 1984 Aug 25; 2(8400):422-4. PubMed ID: 6147500
    [Abstract] [Full Text] [Related]

  • 3. Circulating immune complexes in lupus erythematosus, scleroderma and dermatomyositis.
    Sølling J, Sølling K, Jacobsen KU.
    Acta Derm Venereol; 1979 Aug 25; 59(5):421-6. PubMed ID: 93365
    [Abstract] [Full Text] [Related]

  • 4. Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera.
    Baatrup G, Jonsson H, Sjöholm A, Sturfelt G, Svehag SE.
    J Clin Lab Immunol; 1988 Jun 25; 26(2):73-9. PubMed ID: 3264027
    [Abstract] [Full Text] [Related]

  • 5. Complement-mediated solubilization of immune complexes in systemic lupus erythematosus.
    Sakurai T, Fujita T, Kono I, Kabashima T, Yamane K, Tamura N, Kashiwagi H.
    Clin Exp Immunol; 1982 Apr 25; 48(1):37-42. PubMed ID: 6979449
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of immune precipitation by complement.
    Hong K, Takata Y, Sayama K, Kozono H, Takeda J, Nakano Y, Kinoshita T, Inoue K.
    J Immunol; 1984 Sep 25; 133(3):1464-70. PubMed ID: 6747294
    [Abstract] [Full Text] [Related]

  • 7. The complement-mediated binding of soluble antibody/dsDNA immune complexes to human neutrophils.
    Taylor RP, Burge J, Horgan C, Shasby DM.
    J Immunol; 1983 Jun 25; 130(6):2656-62. PubMed ID: 6854016
    [Abstract] [Full Text] [Related]

  • 8. Hydralazine binds covalently to complement component C4. Different reactivity of C4A and C4B gene products.
    Sim E, Law SK.
    FEBS Lett; 1985 May 20; 184(2):323-7. PubMed ID: 3873356
    [Abstract] [Full Text] [Related]

  • 9. The role of complement in the aetiopathogenesis of systemic lupus erythematosus.
    Gatenby PA.
    Autoimmunity; 1991 May 20; 11(1):61-6. PubMed ID: 1839881
    [Abstract] [Full Text] [Related]

  • 10. Kinetic analysis of immune complex solubilization: complement function in relation to disease activity in SLE.
    Sturfelt G, Nived O, Sjöholm AG.
    Clin Exp Rheumatol; 1992 May 20; 10(3):241-7. PubMed ID: 1582069
    [Abstract] [Full Text] [Related]

  • 11. The clinical value of serum immune complexes in human glomerulonephritis.
    Schena FP, Losuriello V, Pertosa G, Penza R.
    Ric Clin Lab; 1980 May 20; 10(1):99-105. PubMed ID: 7466167
    [No Abstract] [Full Text] [Related]

  • 12. Pleural fluid complement, complement conversion, and immune complexes in immunologic and nonimmunologic diseases.
    Hunder GG, McDuffie FC, Huston KA, Elveback LR, Hepper NG.
    J Lab Clin Med; 1977 Dec 20; 90(6):971-80. PubMed ID: 597373
    [Abstract] [Full Text] [Related]

  • 13. Hypercatabolism of C3 and C4 in active and inactive systemic lupus erythematosus.
    Charlesworth JA, Peake PW, Golding J, Mackie JD, Pussell BA, Timmermans V, Wakefield D.
    Ann Rheum Dis; 1989 Feb 20; 48(2):153-9. PubMed ID: 2784659
    [Abstract] [Full Text] [Related]

  • 14. Interaction of nucleophilic compounds with complement component C4.
    Sim E, Wood M, Parker KE, Jones A.
    Comp Immunol Microbiol Infect Dis; 1988 Feb 20; 11(3-4):163-70. PubMed ID: 3146461
    [Abstract] [Full Text] [Related]

  • 15. Increased amounts of C4-containing immune complexes and inefficient activation of C3 and the terminal complement pathway in a patient with homozygous C2 deficiency and systemic lupus erythematosus.
    Garred P, Mollnes TE, Thorsteinsson L, Erlendsson K, Steinsson K.
    Scand J Immunol; 1990 Jan 20; 31(1):59-64. PubMed ID: 2300790
    [Abstract] [Full Text] [Related]

  • 16. Degradation of soluble immunoglobulin aggregates in vitro by monocytes from normal subjects and from patients with systemic lupus erythematosus.
    Daha MR, van ES LA, Hazevoet HM, Kijlstra A.
    Scand J Immunol; 1982 Aug 20; 16(2):117-22. PubMed ID: 7134889
    [Abstract] [Full Text] [Related]

  • 17. Drug-induced immune-complex disease.
    Sim E.
    Complement Inflamm; 1989 Aug 20; 6(2):119-26. PubMed ID: 2524348
    [Abstract] [Full Text] [Related]

  • 18. Complement C4 and drug-induced SLE.
    Lancet; 1984 Aug 25; 2(8400):441-2. PubMed ID: 6147508
    [No Abstract] [Full Text] [Related]

  • 19. Binding of complement components C1q, C3, C4 and C5 to a model immune complex in ELISA.
    Larsson A, Sjöquist J.
    J Immunol Methods; 1989 Apr 21; 119(1):103-9. PubMed ID: 2785142
    [Abstract] [Full Text] [Related]

  • 20. Complement system protein C4 and susceptibility to hydralazine-induced systemic lupus erythematosus.
    Speirs C, Fielder AH, Chapel H, Davey NJ, Batchelor JR.
    Lancet; 1989 Apr 29; 1(8644):922-4. PubMed ID: 2565418
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.